Compare RAVE & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | MDAI |
|---|---|---|
| Founded | 1958 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.8M | 48.8M |
| IPO Year | N/A | N/A |
| Metric | RAVE | MDAI |
|---|---|---|
| Price | $3.19 | $1.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.25 |
| AVG Volume (30 Days) | 38.2K | ★ 294.4K |
| Earning Date | 02-05-2026 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.08 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | $12,202,000.00 | ★ $23,168,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.24 | ★ N/A |
| Revenue Growth | ★ 0.73 | N/A |
| 52 Week Low | $2.01 | $1.04 |
| 52 Week High | $3.75 | $3.21 |
| Indicator | RAVE | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 49.86 |
| Support Level | $3.15 | $1.49 |
| Resistance Level | $3.40 | $1.69 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 21.17 | 50.68 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.